Verification
How to Verify a Tirzepatide Compounding Pharmacy
Verifying a compounding pharmacy means confirming four things before you pay: its legal name, its state licence and that licence's current status, whether it operates as a 503A pharmacy or a 503B outsourcing facility, and any disciplinary history. All four are checkable against public state board records, which is what makes them meaningful.
Key takeaways
- Ask for the pharmacy's legal name and state licence number before paying, not after.
- Verify the licence directly with that state's board of pharmacy rather than trusting a provider's claim.
- Establish whether the facility is 503A or 503B — the regulatory requirements differ.
- Check for disciplinary action, which state boards publish.
- A provider that will not name its pharmacy before enrolment has told you something important.
| Check 1 | Legal name of the compounding pharmacy |
|---|---|
| Check 2 | State licence number and current status |
| Check 3 | 503A pharmacy or 503B outsourcing facility |
| Check 4 | Disciplinary history published by the state board |
| Where to verify | The relevant state board of pharmacy |
| When to ask | Before payment |
Why is pharmacy verification the substitute for trial evidence?
Because no randomised trial has evaluated any compounded tirzepatide product, so the usual question — what does the evidence show about this product — has no answer. What remains checkable is the chain that produced it: who compounded it, under what licence, in what category of facility, with what regulatory history.
That is a weaker assurance than trial evidence. It is also the only assurance available, which makes skipping it a poor decision.
What does each check actually tell you?
The legal name lets you look up the entity rather than a brand. The licence number and status confirm the pharmacy is currently authorised to operate in a state. The 503A versus 503B distinction determines which regulatory requirements apply, including whether products can be made in batches without patient-specific prescriptions. Disciplinary history reveals prior regulatory findings.
Together they establish whether you are dealing with a licensed operation in good standing or something else.
What if a provider refuses to name its pharmacy?
Treat it as a finding. There is no legitimate confidentiality reason a patient cannot know which pharmacy will prepare their medication — the information appears on the label of what arrives. A refusal before purchase usually means either the provider does not want the pharmacy compared, or it uses several and cannot say which will fill your order.
Either way, the verification you were planning becomes impossible, which is itself the answer.
- Request the compounding pharmacy's legal name in writing before paying.
- Request its state licence number and the state of licensure.
- Search that state's board of pharmacy licence lookup for current status.
- Ask whether it is registered as a 503A pharmacy or 503B outsourcing facility.
- Search the board's disciplinary actions for the entity name.
- Ask for the preparation's concentration in mg/mL and beyond-use date policy.
- Keep the answers — they are your record if a problem arises.
What the evidence shows
- That pharmacy licensure and disciplinary history are publicly checkable through state boards.
- That 503A and 503B facilities operate under different requirements.
What the evidence does not show
- That a verified licence guarantees product quality.
- That verification substitutes for the absent trial evidence — it is weaker.
Related: 503A versus 503B · Red flags
What exactly differs between approved and compounded tirzepatide?
| Attribute | FDA-approved (Zepbound / Mounjaro) | Compounded tirzepatide |
|---|---|---|
| Premarket FDA review | Yes — safety, efficacy, and quality reviewed | No |
| Randomised trial evidence | SURMOUNT and SURPASS programmes | None identified |
| Concentration | Fixed and verified by the manufacturer | Varies by pharmacy; not independently verified |
| Presentation | Fixed-dose pen or autoinjector | Commonly a vial requiring measurement |
| Dating | Manufacturer expiry from stability testing | Pharmacy-assigned beyond-use date |
| Adverse-event capture | Systematic post-marketing surveillance | Less systematic |
| Consumer verification route | FDA approval record | State board licence lookup |
| Group | FDA-approved | Compounded |
|---|---|---|
| Randomised trials | 6 | 0 |
| Verified concentration | 1 | 0 |
| Premarket review | 1 | 0 |
What does the regulatory framework actually say?
Compounding occupies a specific legal position that is frequently described inaccurately in marketing. A 503A pharmacy prepares patient-specific preparations against individual prescriptions and is licensed by a state board of pharmacy. A 503B outsourcing facility may prepare larger batches without individual prescriptions, registers with the FDA, and is subject to current good manufacturing practice requirements. Neither route produces an FDA-approved product.
That last sentence is the one most often blurred. Registration is not approval. Inspection is not approval. Operating legally is not approval. Approval is a specific determination that the FDA has reviewed evidence of safety, effectiveness, and manufacturing quality for a particular product before it is marketed, and no compounded preparation has been through that process.
| Term | What it actually means | What it does not mean |
|---|---|---|
| FDA approved | The agency reviewed safety, efficacy and quality evidence before marketing | Applies to any compounded preparation |
| FDA registered | The facility filed a registration with the agency | The product was reviewed or approved |
| FDA inspected | The agency conducted a facility inspection | The product was approved, or that the inspection found no problems |
| State licensed | A state board authorised the pharmacy to operate | Any federal review of the product |
| cGMP compliant | The facility follows manufacturing practice standards | The specific product was evaluated for safety or efficacy |
| Third-party tested | A laboratory analysed a sample | Systematic batch verification, unless the scope and frequency are disclosed |
What can a patient actually verify before paying?
Where randomised evidence is absent, verification of the supply chain takes its place as the meaningful check. The useful feature of these checks is that they are all things a reader can do independently, against public records, before any money changes hands.
| Check | How to do it | What a refusal or gap tells you |
|---|---|---|
| Pharmacy legal name | Ask the provider in writing before enrolling | A provider unwilling to name its pharmacy is withholding the single most useful fact |
| State licence | Search the licensing state board's public register | An unlisted or lapsed licence is disqualifying |
| 503A or 503B status | Ask, then check the FDA outsourcing facility register for 503B claims | A 503B claim absent from the register is a serious discrepancy |
| Disciplinary history | State board records and enforcement notices | Prior action is not automatically disqualifying but is material |
| Concentration in mg/mL | Ask before ordering; confirm on the dispensing label | An unwillingness to state concentration makes safe use impossible |
| Beyond-use date policy | Ask what date is assigned and on what basis | No stated policy suggests weak quality systems |
| Cold-chain and excursion policy | Ask who bears risk if a shipment arrives warm | No policy means the risk sits with you |
A provider that answers all seven readily has demonstrated something meaningful. One that treats these as intrusive has also answered, in a different way. This is not a guarantee of quality — it is the strongest signal available to a consumer in a market where the usual guarantee, regulatory approval, does not exist.
What are the limits of what this page can tell you?
This page describes a regulatory framework and a verification method. Both have limits that matter.
- Regulatory status changes, and enforcement priorities change with it. Statements here carry the verification date shown above.
- State licensing requirements differ, so a check that is straightforward in one state may be harder in another.
- Verification of a pharmacy's licence establishes that it is authorised to operate. It does not establish the quality of any particular preparation.
- No verification step available to a consumer substitutes for the premarket review that approved products undergo.
What does this page cover, and what does it deliberately leave out?
This page addresses Identity, license, address, 503A/503B and inspections and discipline, organised around the primary question of tirzepatide compounding pharmacy. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Identity | Covered on this page | Regulatory or policy source |
| License | Covered on this page | Regulatory or policy source |
| Address | Covered on this page | Regulatory or policy source |
| 503a/503b | Covered on this page | Regulatory or policy source |
| Inspections and discipline | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the state board of pharmacy and the provider |
What are the limits of what this page can tell you?
Every page on this site rests on a specific pharmacy verification record, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the state board of pharmacy and the provider.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This conclusion is held open to the following evidence:
- New primary evidence bearing directly on tirzepatide compounding pharmacy.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 5 technical terms this page uses, including 503A, 503B, beyond-use date, compounded — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| beyond-use date | The date after which a compounded preparation should not be used. It is assigned by the compounding pharmacy based on its own conditions, and is typically much shorter than a manufacturer expiry date derived from formal stability testing. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| mg/mL | Milligrams of drug per millilitre of liquid — the concentration. Two vials containing the same nominal dose can require different injection volumes if their concentrations differ, which is why this site does not publish volume calculations. |
Frequently asked questions
How do I check a compounding pharmacy?
Get the legal name and state licence number, then verify status and disciplinary history with that state's board of pharmacy.
What if the provider won't name the pharmacy?
Treat that as a meaningful finding — it makes verification impossible before you pay.
Does a valid licence mean the product is good?
No. Licensure confirms authorisation to operate; it does not verify the specific preparation.
What is the difference between 503A and 503B?
Different regulatory categories with different requirements — see 503A versus 503B.
When should I ask these questions?
Before paying. After enrolment you have less leverage and may have prepaid.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.